Thursday, 15 October 2026European Markets

ENSURGE MICROPOWER Stock Was 18.26% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with ENSURGE MICROPOWER (ENSU.OL) rising 18.26% to kr2.11 on Monday, after five sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 1.37% to kr1,390.11, following the last session's upward trend on what was an all-around up trend exchanging session today.

ENSURGE MICROPOWER's last close was kr1.79, 57.37% below its 52-week high of kr4.19.

About ENSURGE MICROPOWER

Ensurge Micropower ASA manufactures and sells ultrathin energy storage solutions for wearable devices, connected sensors, and other applications. Its solid-state lithium battery technology enables it to produce rechargeable batteries. The company was formerly known as Thin Film Electronics ASA and changed its name to Ensurge Micropower ASA in June 2021. Ensurge Micropower ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ENSURGE MICROPOWER has a trailing twelve months EPS of kr-3.86.

Volume

Today's last reported volume for ENSURGE MICROPOWER is 22858700 which is 28.89% above its average volume of 17734900.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ENSURGE MICROPOWER's EBITDA is -150.46.

Yearly Top and Bottom Value

ENSURGE MICROPOWER's stock is valued at kr2.11 at 22:32 EST, way below its 52-week high of kr4.19 and way higher than its 52-week low of kr0.10.

More news about ENSURGE MICROPOWER (ENSU.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com